

# Daniele Morelli

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3268577/publications.pdf>

Version: 2024-02-01

48  
papers

1,824  
citations

304743

22  
h-index

265206

42  
g-index

49  
all docs

49  
docs citations

49  
times ranked

3442  
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 Vaccination in Health Care Workers in Italy: A Literature Review and a Report from a Comprehensive Cancer Center. <i>Vaccines</i> , 2022, 10, 734.	4.4	0
2	Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study. <i>Scientific Reports</i> , 2019, 9, 12993.	3.3	21
3	Baseline and Postoperative C-reactive Protein Levels Predict Long-Term Survival After Lung Metastasectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 869-875.	1.5	12
4	Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study. <i>European Journal of Surgical Oncology</i> , 2018, 44, 792-798.	1.0	21
5	Inflammatory status and lung function predict mortality in lung cancer screening participants. <i>European Journal of Cancer Prevention</i> , 2018, 27, 289-295.	1.3	12
6	Effect of Tobacco Smoking Cessation on C-Reactive Protein Levels in A Cohort of Low-Dose Computed Tomography Screening Participants. <i>Scientific Reports</i> , 2018, 8, 12908.	3.3	33
7	Early detection of colorectal adenocarcinoma: a clinical decision support tool based on plasma porphyrin accumulation and risk factors. <i>BMC Cancer</i> , 2018, 18, 841.	2.6	13
8	C-reactive protein level predicts mortality in COPD: a systematic review and meta-analysis. <i>European Respiratory Review</i> , 2017, 26, 160070.	7.1	61
9	Baseline and postoperative C-reactive protein levels predict mortality in operable lung cancer. <i>European Journal of Cancer</i> , 2017, 79, 90-97.	2.8	34
10	Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy. <i>Head and Neck</i> , 2016, 38, E1009-13.	2.0	6
11	Baseline C-Reactive Protein Level Predicts Survival of Early-Stage Lung Cancer: Evidence from a Systematic Review and Meta-Analysis. <i>Tumori</i> , 2016, 102, 441-449.	1.1	39
12	High SPARC Expression Starting from Dysplasia, Associated with Breast Carcinoma, Is Predictive for Bone Metastasis without Enhancement of Plasma Levels. <i>International Journal of Molecular Sciences</i> , 2015, 16, 28108-28122.	4.1	12
13	The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). <i>European Journal of Surgical Oncology</i> , 2015, 41, 1097-1105.	1.0	22
14	A lipemia-independent NanoDrop <sup>®</sup> -based score to identify hemolysis in plasma and serum samples. <i>Bioanalysis</i> , 2014, 6, 1215-1226.	1.5	47
15	Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. <i>Annals of Oncology</i> , 2014, 25, 352-357.	1.2	53
16	Influence of fatty acid-free diet on mammary tumor development and growth rate in HER2/neu transgenic mice. <i>Journal of Cellular Physiology</i> , 2013, 228, 242-249.	4.1	7
17	Preventing weight gain during adjuvant chemotherapy for breast cancer: a dietary intervention study. <i>Breast Cancer Research and Treatment</i> , 2012, 135, 581-589.	2.5	47
18	Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. <i>Journal of Cellular Physiology</i> , 2012, 227, 658-667.	4.1	410

#	ARTICLE	IF	CITATIONS
19	Induction of Paneth cell degranulation by orally administered Tollâ€like receptor ligands. <i>Journal of Cellular Physiology</i> , 2012, 227, 1107-1113.	4.1	56
20	Lifestyle and breast cancer recurrences: the DIANA-5 trial. <i>Tumori</i> , 2012, 98, 1-18.	1.1	48
21	Influence of Lignans Depletion on Murine Mammary Gland Morphology. <i>Nutrition and Cancer</i> , 2010, 62, 237-242.	2.0	3
22	Serum Insulin-Like Growth Factor-I and Platelet-Derived Growth Factor as Biomarkers of Breast Cancer Prognosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1719-1722.	2.5	49
23	Equol Status Modifies the Association of Soy Intake and Mammographic Density in a Sample of Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 33-42.	2.5	29
24	Natural Fluorescence Spectroscopy of Human Blood Plasma in the Diagnosis of Colorectal Cancer: Feasibility Study and Preliminary Results. <i>Tumori</i> , 2007, 93, 567-571.	1.1	31
25	Influence of Antibiotic Treatment on Breast Carcinoma Development in Proto-neu Transgenic Mice. <i>Cancer Research</i> , 2006, 66, 6219-6224.	0.9	43
26	Antitumor Activity of Human CD34+Cells Expressing Membrane-Bound Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. <i>Human Gene Therapy</i> , 2006, 17, 1225-1240.	2.7	33
27	CpGâ€oligodeoxynucleotides induce mobilization of hematopoietic progenitor cells into peripheral blood in association with mouse KC (ILâ€8) production. <i>Journal of Cellular Physiology</i> , 2005, 204, 889-895.	4.1	26
28	Independent Validation of Candidate Breast Cancer Serum Biomarkers Identified by Mass Spectrometry. <i>Clinical Chemistry</i> , 2005, 51, 2229-2235.	3.2	166
29	Role of HER2 in wound-induced breast carcinoma proliferation. <i>Lancet, The</i> , 2003, 362, 527-533.	13.7	152
30	Immunization of Patients with Malignant Melanoma with Autologous CD34+Cell-Derived Dendritic Cells TransducedEx Vivowith a Recombinant Replication-Deficient Vaccinia Vector Encoding the Human Tyrosinase Gene: A Phase I Trial. <i>Human Gene Therapy</i> , 2003, 14, 1347-1360.	2.7	22
31	Identification of Breast Cancer-Restricted Antigens by Antibody Screening of SKBR3 cDNA Library Using a Preselected Patient's Serum. <i>Breast Cancer Research and Treatment</i> , 2002, 73, 245-256.	2.5	59
32	Letter to the editor. <i>Breast Cancer Research and Treatment</i> , 2001, 70, 155-156.	2.5	10
33	Topical administration of a doxorubicin-specific monoclonal antibody prevents drug-induced mouth apoptosis in mice. <i>British Journal of Cancer</i> , 2001, 85, 1964-1967.	6.4	5
34	High level antibody response to retrovirus-associated but not to melanocyte lineage-specific antigens in mice protected against B16 melanoma. , 1999, 83, 107-112.		4
35	INHIBITION OF FIBRONECTIN-ACTIVATED MIGRATION OF MICROVASCULAR ENDOTHELIAL CELLS BY INTERLEUKIN-1±, TUMOUR NECROSIS FACTOR Î± AND INTERFERON Î³. <i>Cytokine</i> , 1999, 11, 134-139.	3.2	8
36	Segregation of type 1 cytokine production in human peripheral blood lymphocytes: phenotypic differences between IFN-Î³ and IL-2-producing cells in the CD8+ T cell subset. <i>European Journal of Immunology</i> , 1998, 28, 3630-3638.	2.9	19

#	ARTICLE	IF	CITATIONS
37	A monoclonal antibody extends the half-life of an anti-HIV oligodeoxynucleotide and targets it to CD4+ cells. <i>Nucleic Acids Research</i> , 1995, 23, 4603-4607.	14.5	4
38	The Differential Response to Interferon $\beta$ by Normal and Transformed Endothelial Cells. <i>Biochemical and Biophysical Research Communications</i> , 1995, 214, 582-588.	2.1	15
39	Modulation of drug-induced cytotoxicity by a bispecific monoclonal antibody that recognizes the epidermal growth factor receptor and doxorubicin. <i>Cancer Immunology, Immunotherapy</i> , 1994, 38, 171-177.	4.2	6
40	Effect of a bifunctional monoclonal antibody directed against a tumor marker and doxorubicin on the growth of epidermoid vulvar carcinoma grafted in athymic mice. <i>Cell Biophysics</i> , 1994, 24-25, 119-126.	0.4	1
41	Relevance of Antibody Valency in EGF Receptor Modulation. <i>Scandinavian Journal of Immunology</i> , 1994, 39, 453-458.	2.7	6
42	Modulation of drug-induced cytotoxicity by a bispecific monoclonal antibody that recognizes the epidermal growth factor receptor and doxorubicin. <i>Cancer Immunology, Immunotherapy</i> , 1994, 38, 171-177.	4.2	7
43	The Detection and Biological Activity of Human Antibodies to IL-2 in Normal Donors. <i>Scandinavian Journal of Immunology</i> , 1993, 38, 472-476.	2.7	35
44	Purification of interleukin-2 antibodies from healthy individuals. <i>Immunology Letters</i> , 1993, 36, 261-266.	2.5	18
45	Increase in the therapeutic effect of doxorubicin induced by monoclonal antibodies raised against this drug. <i>Pharmacological Research</i> , 1992, 26, 141-143.	7.1	0
46	An anti-doxorubicin monoclonal antibody modulates kinetic and dynamic characteristics of the drug. <i>International Journal of Cancer</i> , 1992, 50, 617-620.	5.1	7
47	Monoclonal antibodies against doxorubicin. <i>International Journal of Cancer</i> , 1988, 42, 798-802.	5.1	15
48	Structural studies on the interaction between ferredoxin and ferredoxin-NADP+ reductase. <i>Biochemistry</i> , 1988, 27, 3753-3759.	2.5	97